Regulatory Forum

Regulatory Forum Opinion Piece: The Value of Publishing Negative Scientific Study Data
Gary A. Boorman, John R. Foster, Victoria A. Laast, and Sabine Francke

Scientific and Regulatory Policy Committee

Scientific and Regulatory Policy Committee Review: Review of the Organisation for Economic Co-operation and Development (OECD) Guidance on the GLP Requirements for Peer Review of Histopathology
James D. Fikes, Daniel J. Patrick, Sabine Francke, Kendall S. Frazier, James F. Reindel, Annette Romeike, Robert H. Spaet, Lindsay Tomlinson, and Kenneth A. Schafer


Invited Review

The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle
Silvia Guionaud

Review

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
Inge A. Ivens, William Achanzar, Andreas Baumann, Annamaria Brändli-Baiocco, Joy Cavagnaro, Maggie Dempster, B. Olympe Depelchin, Armando R. Irizarry Rovira, Laura Dill-Morton, Joan H. Lane, Birgit M. Reipert, Theodora Salcedo, Becky Schweighardt, Laurie S. Tsuruda, Peter L. Turecek, and Jennifer Sims

Cover: The administration of recombinant interleukin 2 (rIL-2) can be associated with time-dependent histologic vascular changes that can present as a vascular leakage syndrome in humans undergoing oncology treatment. The changes in male Han Wistar rats associated with this drug induced vascular injury (DIVI) were characterized by endothelial hypertrophy/hyperplasia and perivascular inflammation. This vascular injury correlated with increases in circulating angiopoietin 2, lipocalin 2, monocyte chemotactic protein-1, tissue inhibitor of metalloproteinase 1, vascular endothelial growth factor A, E-selectin, and chemokine (C-X-C motif) ligand 1, and the microRNAs miR-21, miR-132 and miR-155. (See Mikaelian et al., pp. 984–994)

Diagnosis: rIL2-mediated Vascular Toxicity
Original Articles

Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat 984
Natalie D. Keirstead, Cristina Bertinetti-Lapatki, Denise Knapp, Mudher Albassam, Valerie Hughes, Feng Hong, Adrian B. Roth, and Igor Mikaelian

Drug-induced Skin Lesions in Cynomolgus Macaques Treated with Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulators 995
Gopinath S. Palanisamy, John M. Marcek, Gregg D. Cappon, Jessica Whitrenour, Christopher L. Shaffer, Joseph T. Brady, and Christopher Houle

Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys 1004
John L. Vahle, Richard A. Byrd, Jamie L. Blackbourne, Jennifer A. Martin, Steven D. Sorden, Thomas Ryan, Thomas Pienkowski, Thomas J. Rosol, Paul W. Snyder, and Günter Klöppel

Detection of Mild and Reversible Neurohistopathological Changes in the Brain of Juvenile (Preweaned) Beagle Dogs Treated with Vigabatrin for up to 91 Days 1015
Anna L. Bottomley, Alison Rowles, David J. Mitchell, and Allan D. Rasmussen

Immunophenotype of Spontaneous Hematolymphoid Tumors Occurring in Young and Aging Female CD-1 Mice 1025
Jerold E. Rehg, Richard Rahija, Dorothy Bush, Aly Bradley, and Jerrold M. Ward

Brief Communication

Asbestosis in a Japanese Macaque (Macaca fuscata) 1035
Kosuke Tsugo, Akane Kashimura, and Yumi Une